Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.

T M Davidson, C L Lebreton,A E Wahner Hendricksen, H J Atkinson,M C Larson,A L Oberg,D M Provencher,J A Glaspy,B Y Karlan,D J Slamon,G E Konecny, I L Ray-Coquard

Gynecologic oncology（2023）

引用 1|浏览26

暂无评分

摘要

IGF1R inhibition with ganitumab was well-tolerated, however, our results do not support further study of ganitumab as a single agent in unselected OC patients.

查看译文

关键词

AMG 479,Ganitumab,IGFR1 inhibitor,Insulin-like growth factor,Ovarian cancer,Targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要